Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 6 February 2018

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

Ablynx    

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

 

GHENT, Belgium, 6 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC on 2 February 2018.

 

FMR LLC (taking into account the holdings of its subsidiary undertakings) now holds a total of 5,886,429 voting securities of Ablynx, representing 7.84% of the current 75,065,990 outstanding voting rights of Ablynx (versus 7.86% notified previously on 1 February 2018).

 

FMR LLC has notified Ablynx that FMR Co., Inc., a subsidiary of Fidelity Management & Research Company, which itself is a subsidiary of FMR LLC (the ultimate parent company) has downward crossed the 3% threshold of voting rights linked to securities of Ablynx and upward crossed the 3% threshold of voting rights of Ablynx held through financial instruments since 31 January 2018.

 

The notification contains the following information:

  • Reason for the notification:
    • acquisition or disposal of financial instruments that are treated as voting securities
    • acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: FMR LLC
  • Transaction date: 31 January 2018
  • Threshold that is crossed: 3% of voting rights linked to securities and 3% of voting rights held through financial instruments
  • Denominator: 75,065,990
  • Details of the notification:

Name of select subsidiaries of

FMR LLC

% of voting rights

% of voting rights held through financial instruments*

Total of both

FMR LLC

Fidelity Management & Research Company

FMR Co., Inc.

2.78%

3.14%

5.92%

FMR LLC

FIAM Holdings Corp.

Fidelity Institutional Asset Management Trust Company

1.04%

 

1.04%

FMR LLC

FIAM Holdings Corp.

FIAM LLC

0.89%

 

0.89%

TOTAL

4.71%

3.14%

7.84%

* Type of financial instrument: "Right of Recall

 

  • Chain of controlled undertakings through which the holding is effectively being held: The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.

 

More information is available in the transparency notification. A full version of the transparency notification is available on Ablynx website, under the section Investors.

 

The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

 

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

 

Lies Vanneste

Director Investor Relations

t:   +32 (0)9 262 01 37

m: +32 (0)498 05 35 79

e:  lies.vanneste@ablynx.com

 

Follow us on Twitter @AblynxABLX

 

Ablynx media relations:

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji

t:  +44 (0)20 3709 5700

e:  ablynx@consilium-comms.com

 

Joele Frank, Wilkinson Brimmer Katcher

Dan Katcher or Joseph Sala

t:  +1 212-355-4449

 

 




pdf version of the press release



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Ablynx, Technologiepark 21, Ghent/Zwijnaarde 9052, Belgiƫ
If you would like to unsubscribe and stop receiving these e-mails click here.